Cancer is the villain who does not just build a lair - it cuts the power to the heroes’ flashlight, steals their snacks, and then acts surprised when nobody can fight properly.
In this story, the heroes are CD8+ T cells, the immune system’s elite little bouncers. Their job is to spot dangerous cells, including cancer cells, and remove them from the premises. But inside tumors, these T cells often become exhausted. Not sleepy in the “watched one more episode” sense. More like: their weapons dull, their engines sputter, and their motivational playlist has been replaced with hold music.
A new study by Liu and colleagues in Cellular & Molecular Immunology points to a possible culprit behind that energy collapse: a protein called PARK7, also known as DJ-1. And yes, “DJ-1” sounds like someone who should be opening for a 2007 dance act, but in this paper it plays a much moodier role [1].
The Heroes Had Engine Trouble
T cells need mitochondria. You probably know mitochondria as the “powerhouse of the cell,” because seventh-grade biology tattooed that phrase onto everyone’s brain. But for immune cells, mitochondria are not just battery packs. They help decide whether a T cell can keep growing, moving, signaling, and killing.
Tumors, unfortunately, are terrible workplaces. Low oxygen, weird nutrients, constant alarm signals, suppressive chemistry - the tumor microenvironment is basically a sketchy neighborhood with bad lighting and a lot of suspicious vans. Over time, CD8+ T cells in that environment can enter exhaustion, marked by weaker attack functions and higher levels of braking receptors like PD-1, TIM-3, and LAG-3.
That is why checkpoint inhibitors, such as anti-PD-1 therapies, can work so well in some cancers. They take the foot off one immune brake. But many patients still do not respond, or respond only partly. One reason may be that exhausted T cells do not just have a brake problem. They may also have an engine problem [2,3].
Enter PARK7, Wearing a Tiny Villain Cape
Liu and colleagues found that PARK7 was enriched in the mitochondria of tumor-infiltrating CD8+ T cells. When the researchers removed PARK7 specifically from T cells in mouse models, those CD8+ T cells showed better mitochondrial function, less exhaustion, and stronger tumor control [1].
That is the big plot turn: PARK7 was not merely hanging around the crime scene. It seemed to help create the conditions that made T cells fade.
The paper then follows the clue trail to ATAD3A, a mitochondrial membrane protein involved in mitochondrial organization and gene expression. Think of ATAD3A as part foreman, part scaffolding manager for the cell’s power plant. Other work has linked ATAD3A to mitochondrial structure, respiratory complex assembly, and cancer-related immune behavior [4,5].
Here, PARK7 physically interacted with ATAD3A and reduced its lactylation.
Lactylation: The Molecular Sticky Note
Lactylation is a chemical tag added to proteins, influenced by lactate metabolism. Lactate used to be treated like cellular exhaust, the biochemical equivalent of gym socks in a locker. Now scientists keep finding that lactate-related chemistry can help regulate genes and proteins. Cancer biology loves a plot twist, because apparently it was written by someone allergic to simplicity.
In this study, ATAD3A lactylation appeared to support mitochondrial gene expression. PARK7 removed or reduced that lactylation signal - “delactylation” - and the downstream effect was poorer mitochondrial fitness in CD8+ T cells [1].
Less mitochondrial fitness means less T cell stamina. Less stamina means more exhaustion. More exhaustion means tumors get a quieter neighborhood.
Why This Could Matter
If these findings hold up in more models and eventually in human tumors, PARK7 could become a new target for cancer immunotherapy. Not as a replacement for checkpoint blockade, but potentially as a way to make T cells healthier before asking them to sprint back into battle.
That matters because current immunotherapy often focuses on releasing brakes. This work suggests another strategy: repair the engine. A T cell with a lifted brake but busted mitochondria is like a getaway car with no gas. Very dramatic, not very useful.
The study also adds to a broader shift in cancer immunology. Researchers increasingly view T cell exhaustion not as a simple “on/off” failure, but as a layered state shaped by chronic stimulation, epigenetic rewiring, metabolism, mitochondrial stress, and the tumor’s local conditions [2,3,6]. That complexity is annoying, scientifically speaking, but it also gives researchers more handles to grab.
The Cliffhanger
There are still big questions. Can PARK7 be targeted safely? Would blocking it help human T cells inside real tumors, not just controlled experimental systems? Could this combine with PD-1 blockade, CAR-T therapy, or metabolic interventions? And does PARK7 play different roles in different cancers?
For now, the story is still in the early chapters. But it gives us a sharp new suspect in the mystery of exhausted tumor-fighting T cells. The villain may be cancer, but PARK7 might be the henchman quietly dimming the lights.
References
-
Liu J, Xu M, Zhou Y, et al. PARK7-induced delactylation of ATAD3A impairs mitochondrial fitness to promote exhaustion of tumor-infiltrating CD8+ T cells. Cellular & Molecular Immunology. 2026. DOI: https://doi.org/10.1038/s41423-026-01425-8
-
Chow A, Perica K, Klebanoff CA, Wolchok JD. Clinical implications of T-cell exhaustion for cancer immunotherapy. Nature Reviews Clinical Oncology. 2022;19:775-790. DOI: https://doi.org/10.1038/s41571-022-00689-z
-
Franco F, Jaccard A, Romero P, Yu YR, Ho PC. Metabolic and epigenetic regulation of T-cell exhaustion. Nature Metabolism. 2020;2:1001-1012. DOI: https://doi.org/10.1038/s42255-020-00280-9
-
Scharping NE, et al. Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T-cell exhaustion. Nature Immunology. 2021;22:205-215. DOI: https://doi.org/10.1038/s41590-020-00834-9
-
Arguello T, et al. ATAD3A has a scaffolding role regulating mitochondria inner membrane structure and protein assembly. Cell Reports. 2021;37:110139. DOI: https://doi.org/10.1016/j.celrep.2021.110139
-
Xie XQ, et al. Targeting ATAD3A-PINK1-mitophagy axis overcomes chemoimmunotherapy resistance by redirecting PD-L1 to mitochondria. Cell Research. 2023;33:215-228. DOI: https://doi.org/10.1038/s41422-022-00766-z
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.